NHS Digital announces patient de-identification software partnership

NHS Digital announces patient de-identification software partnership

July 5 2018 NHS Digital will introduce new software for the de-identification of patient...

Over half of acute trusts are now using GP e-Referral Service

Over half of acute trusts are now using GP e-Referral Service

June 14 2018 More than 50% of acute hospital trusts in England have switched off paper referrals...

NEWS app for sepsis scoring available

NEWS app for sepsis scoring available

June 4 2018 An app has been re-launched to help clinicians staff across NHS Wales calculate an...

NHS launches National Data Opt-Out facility

NHS launches National Data Opt-Out facility

May 31 2018 NHS patients can formally opt out of having their data used for research or planning...

ePACT to be decommissioned on June 8 as ePACT2 takes over

ePACT to be decommissioned on June 8 as ePACT2 takes over

May 29 2018 NHS Business Services Authority will decommission ePACT with effect from June 8, as...

  • NHS Digital announces patient de-identification software partnership

    NHS Digital announces patient de-identification software partnership

    Thursday, 05 July 2018 16:48
  • Over half of acute trusts are now using GP e-Referral Service

    Over half of acute trusts are now using GP e-Referral Service

    Thursday, 14 June 2018 14:29
  • NEWS app for sepsis scoring available

    NEWS app for sepsis scoring available

    Monday, 04 June 2018 09:58
  • NHS launches National Data Opt-Out facility

    NHS launches National Data Opt-Out facility

    Thursday, 31 May 2018 09:01
  • ePACT to be decommissioned on June 8 as ePACT2 takes over

    ePACT to be decommissioned on June 8 as ePACT2 takes over

    Tuesday, 29 May 2018 12:48

adhdDecember 2 2015

Researchers have urged doctors to be cautious if considering prescribing methylphenidate for children or adolescents with attention deficit hyperactivity disorder (ADHD).

A Cochrane review has concluded that the drug may improve teacher-reported ADHD symptoms, teacher-reported general behaviour, and parent-reported quality of life among children and adolescents diagnosed with ADHD. “However, the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects.”

The researchers assessed 38 parallel-group trials and 147 cross-over trials, representing over 12,200 patients, and found methylphenidate led to “modest” improvements in ADHD symptoms as a primary outcome. They also found there were improvements in general behaviour and quality of life. However, in all outcomes, the quality of the evidence was judged to be “very low”.

Data for serious adverse events was only reported in nine out of the 185 trials, meaning that while methylphenidate does not appear to be associated with an increased risk of serious adverse events, the quality of the evidence was again very low.

“It was apparent from assessing the included trials that it would have been possible for people involved in the trials to have been aware of which treatment the children were taking,” says Cochrane. “In addition, the reporting of results was not complete in many of the trials, and for some analyses there was variation among trial results.

“Based upon this information, the researchers urge clinicians to be cautious in prescribing methylphenidate, and to weigh up the benefits and risks more carefully.”

Professor Ole Jakob Storebø, a clinical psychologist from the Psychiatric Research Unit in Region Zealand, Denmark, led the team of 18 researchers carrying out the meta-analysis. “This review highlights the need for long-term, large, better-quality randomized trials so that we can determine the average effect of this drug more reliably,” he said.

Co-author Camilla Groth MD added: “This review shows very limited quality evidence for the effects of methylphenidate on children and adolescents with ADHD. Some might benefit, but we still don’t know which patients will do so. Clinicians prescribing methylphenidate must take account of the poor quality of the evidence, monitor treatment carefully, and weigh up the benefits and adverse effects.”

Links:

Cochrane announcement

Cochrane review summary

Ole Jakob Storebø et al. ‘Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)’. Cochrane Library. Published online November 25 2015.

Management News

July 27 2018 Adolescent boys will be offered the human papilloma virus (HPV) vaccine to protect them from cancer, the Department of Health and Social Care has announced.
July 20 2018 Doctors are being reminded to ensure that any patient or other records which may be relevant to the UK Infected Blood Inquiry are not destroyed. Earlier this month, the Inquiry’s Chair, Sir...